Affiliation:
1. Department of Biobehavioral Health Sciences, School of Nursing University of Pennsylvania Philadelphia Pennsylvania USA
2. Department of Psychiatry University of Pennsylvania, Perelman School of Medicine Philadelphia Pennsylvania USA
3. Department of Biological Sciences, Human and Evolutionary Biology Section University of Southern California Los Angeles California USA
Abstract
AbstractBackgroundNausea and emesis are ubiquitously reported medical conditions and often present as treatment side effects along with polymorbidities contributing to detrimental life‐threatening outcomes, such as poor nutrition, lower quality of life, and unfavorable patient prognosis. Growth differentiation factor 15 (GDF15) is a stress response cytokine secreted by a wide variety of cell types in response to a broad range of stressors. Circulating GDF15 levels are elevated in a range of medical conditions characterized by cachexia and malaise. In recent years, GDF15 has gained scientific and translational prominence with the discovery that its receptor, GDNF family receptor α‐like (GFRAL), is expressed exclusively in the hindbrain. GFRAL activation may results in profound anorexia and body weight loss, effects which have attracted interest for the pharmacological treatment of obesity.PurposeThis review highlights compelling emerging evidence indicating that GDF15 causes anorexia through the induction of nausea, emesis, and food aversions, which encourage a perspective on GDF15 system function in physiology and behavior beyond homeostatic energy regulation contexts. This highlights the potential role of GDF15 in the central mediation of nausea and emesis following a variety of physiological, and pathophysiological conditions such as chemotherapy‐induced emesis, hyperemesis gravidarum, and cyclic vomiting syndrome.
Funder
National Institute of Diabetes and Digestive and Kidney Diseases